212 related articles for article (PubMed ID: 22054413)
1. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
3. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
[TBL] [Abstract][Full Text] [Related]
4. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
5. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
[TBL] [Abstract][Full Text] [Related]
6. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
Sawada T; Fuchinoue S; Teraoka S
Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
9. Use of ABO-incompatible grafts in living donor liver transplantation--first report from India.
Soin AS; Raut V; Mohanka R; Rastogi A; Goja S; Balachandran M; Saigal S; Saraf N; Bhangui P; Sumana KR; Singla P; Srinivasan T; Choudhary N; Tiwari A; Raina V; Govil D; Mohan N; Vohra V
Indian J Gastroenterol; 2014 Jan; 33(1):72-6. PubMed ID: 24369388
[TBL] [Abstract][Full Text] [Related]
10. ABO-incompatible kidney transplantation in elderly patients over 60 years of age.
Uchida J; Iwai T; Machida Y; Kuwabara N; Kabei K; Murao M; Otoshi T; Naganuma T; Kumada N; Nakatani T
Int Urol Nephrol; 2012 Oct; 44(5):1563-70. PubMed ID: 22828739
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
[TBL] [Abstract][Full Text] [Related]
12. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience.
Shirakawa H; Ishida H; Shimizu T; Omoto K; Iida S; Toki D; Tanabe K
Clin Transplant; 2011; 25(6):878-84. PubMed ID: 21175849
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
14. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
15. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
16. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
[TBL] [Abstract][Full Text] [Related]
17. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab.
Raut V; Mori A; Kaido T; Ogura Y; Taku I; Nagai K; Sasaki N; Endo K; Hata T; Yagi S; Egawa H; Uemoto S
Transplantation; 2012 Jan; 93(1):99-105. PubMed ID: 22094955
[TBL] [Abstract][Full Text] [Related]
18. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
19. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
[TBL] [Abstract][Full Text] [Related]
20. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.
Sonnenday CJ; Warren DS; Cooper M; Samaniego M; Haas M; King KE; Shirey RS; Simpkins CE; Montgomery RA
Am J Transplant; 2004 Aug; 4(8):1315-22. PubMed ID: 15268734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
